강심제 시장(2025-2029년)

The global inotropic agents market is forecasted to grow by USD 1961.6 mn during 2024-2029, accelerating at a CAGR of 12.0% during the forecast period. The report on the global inotropic agents market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of cardiovascular diseases, growing proportion of aging population, rising healthcare expenditure and heightened awareness.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global inotropic agents market is segmented as below:

By Route Of Administration

• Parenteral
• Oral
• Others

By Type

• Positive inotropic drugs
• Negative inotropic drugs
• Others

By End-User

• Hospitals
• Homecare
• Specialty centers
• Others

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the paradigm shift towards novel inotropic agents with improved safety profiles as one of the prime reasons driving the global inotropic agents market growth during the next few years. Also, increasing adoption of outpatient and home-based inotropic therapy and strategic implementation of combination therapies will lead to sizable demand in the market.

The report on the global inotropic agents market covers the following areas:

• Global inotropic agents market sizing
• Global inotropic agents market forecast
• Global inotropic agents market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global inotropic agents market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Baxter International Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., Cipla Inc., Eli Lilly and Co., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson Services, Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Viatris Inc.. Also, the global inotropic agents market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2024
• 4.4 Market outlook: Forecast for 2024-2029

5 Historic Market Size

• 5.1 Global Inotropic Agents Market 2019 - 2023
  • Historic Market Size - Data Table on Global Inotropic Agents Market 2019 - 2023 ($ million)
• 5.2 Route of Administration segment analysis 2019 - 2023
  • Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million)
• 5.3 Type segment analysis 2019 - 2023
  • Historic Market Size - Type Segment 2019 - 2023 ($ million)
• 5.4 End-user segment analysis 2019 - 2023
  • Historic Market Size - End-user Segment 2019 - 2023 ($ million)
• 5.5 Geography segment analysis 2019 - 2023
  • Historic Market Size - Geography Segment 2019 - 2023 ($ million)
• 5.6 Country segment analysis 2019 - 2023
  • Historic Market Size - Country Segment 2019 - 2023 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI in global inotropic agents market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2024 and 2029
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2024 and 2029
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2024 and 2029
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2024 and 2029
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2024 and 2029
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2024 and 2029
• 7.7 Market condition

8 Market Segmentation by Route of Administration

• 8.1 Market segments
• 8.2 Comparison by Route of Administration
• 8.3 Parenteral - Market size and forecast 2024-2029
• 8.4 Oral - Market size and forecast 2024-2029
• 8.5 Others - Market size and forecast 2024-2029
• 8.6 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)

9 Market Segmentation by Type

• 9.1 Market segments
• 9.2 Comparison by Type
• 9.3 Positive inotropic drugs - Market size and forecast 2024-2029
• 9.4 Negative inotropic drugs - Market size and forecast 2024-2029
• 9.5 Others - Market size and forecast 2024-2029
• 9.6 Market opportunity by Type
  • Market opportunity by Type ($ million)

10 Market Segmentation by End-user

• 10.1 Market segments
• 10.2 Comparison by End-user
• 10.3 Hospitals - Market size and forecast 2024-2029
• 10.4 Homecare - Market size and forecast 2024-2029
• 10.5 Specialty centers - Market size and forecast 2024-2029
• 10.6 Others - Market size and forecast 2024-2029
• 10.7 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2024-2029
  • 12.3.1 US - Market size and forecast 2024-2029
  • 12.3.2 Canada - Market size and forecast 2024-2029
  • 12.3.3 Mexico - Market size and forecast 2024-2029
• 12.4 Europe - Market size and forecast 2024-2029
  • 12.4.1 Germany - Market size and forecast 2024-2029
  • 12.4.2 UK - Market size and forecast 2024-2029
  • 12.4.3 France - Market size and forecast 2024-2029
  • 12.4.4 Russia - Market size and forecast 2024-2029
  • 12.4.5 Italy - Market size and forecast 2024-2029
  • 12.4.6 Spain - Market size and forecast 2024-2029
  • 12.4.7 The Netherlands - Market size and forecast 2024-2029
• 12.5 Asia - Market size and forecast 2024-2029
  • 12.5.1 China - Market size and forecast 2024-2029
  • 12.5.2 Japan - Market size and forecast 2024-2029
  • 12.5.3 India - Market size and forecast 2024-2029
  • 12.5.4 South Korea - Market size and forecast 2024-2029
  • 12.5.5 Singapore - Market size and forecast 2024-2029
  • 12.5.6 Thailand - Market size and forecast 2024-2029
  • 12.5.7 Indonesia - Market size and forecast 2024-2029
• 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
  • 12.6.1 Brazil - Market size and forecast 2024-2029
  • 12.6.2 Turkey - Market size and forecast 2024-2029
  • 12.6.3 Saudi Arabia - Market size and forecast 2024-2029
  • 12.6.4 South Africa - Market size and forecast 2024-2029
  • 12.6.5 Australia - Market size and forecast 2024-2029
  • 12.6.6 UAE - Market size and forecast 2024-2029
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Increasing prevalence of cardiovascular diseases
  • Growing proportion of aging population
  • Rising healthcare expenditure and heightened awareness
• 13.2 Market challenges
  • Stringent regulatory hurdles and high clinical trial costs
  • Adverse side effects and enduring safety concerns
  • Competition from advanced therapies and novel drug classes
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2024 and 2029
• 13.4 Market opportunities
  • Paradigm shift towards novel inotropic agents with improved safety profiles
  • Increasing adoption of outpatient and home-based inotropic therapy
  • Strategic implementation of combination therapies

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Product / Service
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • SWOT
• 15.5 Amgen Inc.
  • Amgen Inc. - Overview
  • Amgen Inc. - Product / Service
  • Amgen Inc. - Key news
  • Amgen Inc. - Key offerings
  • SWOT
• 15.6 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product / Service
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • SWOT
• 15.7 Baxter International Inc.
  • Baxter International Inc. - Overview
  • Baxter International Inc. - Business segments
  • Baxter International Inc. - Key news
  • Baxter International Inc. - Key offerings
  • Baxter International Inc. - Segment focus
  • SWOT
• 15.8 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key news
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 15.9 Boehringer Ingelheim GmbH
  • Boehringer Ingelheim GmbH - Overview
  • Boehringer Ingelheim GmbH - Product / Service
  • Boehringer Ingelheim GmbH - Key news
  • Boehringer Ingelheim GmbH - Key offerings
  • SWOT
• 15.10 Bristol Myers Squibb Co.
  • Bristol Myers Squibb Co. - Overview
  • Bristol Myers Squibb Co. - Product / Service
  • Bristol Myers Squibb Co. - Key news
  • Bristol Myers Squibb Co. - Key offerings
  • SWOT
• 15.11 Eli Lilly and Co.
  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Product / Service
  • Eli Lilly and Co. - Key offerings
  • SWOT
• 15.12 GlaxoSmithKline Plc
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key news
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Segment focus
  • SWOT
• 15.13 Hikma Pharmaceuticals Plc
  • Hikma Pharmaceuticals Plc - Overview
  • Hikma Pharmaceuticals Plc - Business segments
  • Hikma Pharmaceuticals Plc - Key news
  • Hikma Pharmaceuticals Plc - Key offerings
  • Hikma Pharmaceuticals Plc - Segment focus
  • SWOT
• 15.14 Johnson and Johnson Services
  • Johnson and Johnson Services - Overview
  • Johnson and Johnson Services - Business segments
  • Johnson and Johnson Services - Key news
  • Johnson and Johnson Services - Key offerings
  • Johnson and Johnson Services - Segment focus
  • SWOT
• 15.15 Merck and Co. Inc.
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key news
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Segment focus
  • SWOT
• 15.16 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 15.17 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Product / Service
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • SWOT
• 15.18 Sanofi SA
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations